BGPT: Paper Review: Hepatic stellate cells do not derive from the neural crest

Explore by Goal

Quick Explanation Copied

Bottom line: Using a constitutive neural-crest lineage tracer (Wnt-1-CRE/ROSA26-YFP), the authors report no detectable YFP in developing or adult hepatic stellate cells (HSCs), arguing HSCs “most likely do not derive from the neural crest.”

Long Explanation

Paper Review (Critical, Evidence-Based): Hepatic stellate cells do not derive from the neural crest

DOI: 10.1016/j.jhep.2005.09.023 • Published: 2005-11-14

1) Visual readout of the central claim

The authors’ key logic is a lineage-tracer negation: if HSCs derived from neural crest, they should inherit YFP from neural crest-lineage cells. They report that desmin+ HSCs appear from E11.5 onward, yet the liver remains YFP− in the same lineage-tracing system.

2) Data-driven visualization (from the paper’s timeline logic)

A compact “expected if neural-crest-derived” vs “observed” schematic, aligned to the paper’s sampling window (E11.5 → adulthood).

3) What the paper actually did (and what it didn’t)

3.1 Experimental strategy

Lineage tracer: double transgenic Wnt-1-CRE/YFP labeling neural crest cells and derivatives with constitutive YFP.
HSC identification: desmin immunostaining to detect stellate-shaped, perisinusoidal HSCs from E11.5 onward.
Comparators/controls: non-transgenic littermates as negative controls and neural-crest-derived structures (e.g., ENS; adrenal medulla) as positive internal checks.

3.2 Critical gap: “non-detection” is not always “absence”

The claim depends on YFP being detectable if lineage contribution exists. This is a powerful approach when the tracer is robust, but it can miss contributions if (i) the relevant neural crest subset does not activate Wnt-1-CRE strongly enough, (ii) YFP fluorescence is below detection threshold in the specific tissue compartment, or (iii) HSC marker timing differs from tracer recombination timing.

The authors acknowledge a “formal exclusion” limitation: a non-Wnt-1-expressing neural crest subset could still contribute.

4) Internal consistency check: does the tracer work?

A skeptic’s first question: if YFP fails in liver due to technical reasons, then the absence of YFP in HSC is uninformative. The paper reports robust YFP labeling of multiple neural crest-derived structures in the same animals (central neural tube/cranial nerves/ENS/adrenal medulla).

5) Interpretation: what can we infer with confidence?

5.1 Strengths

Lineage-tracing within the same animal provides a stringent internal comparison between neural crest derivatives (YFP+) and liver (YFP−).
Temporal alignment between HSC appearance (desmin+) and lack of YFP in liver argues against a late-arriving lineage contribution.
Internal positive controls (ENS; adrenal medulla) support that the tracer is not globally silent.

5.2 Limitations / blind spots (skeptical, testable)

Coverage of neural crest subsets: the authors concede that a neural crest subset not governed by the Wnt-1 regulatory element could escape labeling and still contribute.
Marker-set constraints: HSC identification is based on desmin in embryos; some other commonly used neural/glial marker logic is discussed as not usable in parallel in this particular mouse-embryo context.
Detection threshold: “no detectable YFP” is sensitive to tissue processing, antibody detection performance, imaging parameters, and reporter stability.

6) Counterpoints to consider (what would change the conclusion?)

What would disprove the central conclusion is conceptually straightforward:

Demonstration of YFP (or another robust neural-crest lineage mark) within HSCs during the same developmental window (E11.5→adulthood) using an orthogonal tracer strategy with confirmed neural-crest subset coverage.
Evidence that Wnt-1-CRE activation is missing from the relevant neural crest subpopulation(s) that contribute to HSCs.

Author reviews (recommended next step)

Explore author-specific framing and likely methodological emphasis.

Feedback:

Updated: April 13, 2026